A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer
To determine the safety and efficacy of Cesamet™ in the symptomatic treatment of
chemotherapy-induced neuropathic pain.
This is a phase IV, multicenter, open label of Cesamet™ at 1 mg daily progressing to 2mg BID
in subjects with chemotherapy-induced neuropathic pain. This study has two phases: A
pretreatment phase and a treatment phase.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The Average Pain Score at target site.
Joseph V Pergolizzi, MD
NEMA Research, Inc.
United States: Institutional Review Board
CB1 Study 003
|South Florida Medical Research||Aventura, Florida 33180|
|Naples Anesthesia and Pain Associates||Naples, Florida 34108|